The goal of this research is to see if giving the drug SCH66336 by mouth can improve the
disease in patients with chronic or accelerated phase CML. The safety of this treatment will
also be studied.
Objectives for this study are two-fold:
1. To determine the efficacy of SCH66336 in patients with chronic phase and accelerated
phase CML in relation to response rate, duration of response, and survival.
2. To assess the toxicity of SCH66366 in these patients.
- Diagnosis of Philadelphia chromosome (Ph) -positive CML in chronic or accelerated
- Failure to respond to or intolerance to imatinib mesylate (Gleevec);
- Age >/= 16 years;
- Life expectancy of >/= 2 months;
- Performance status 2 or better (Zubrod);
- Adequate renal and hepatic functions (creatinine and bilirubin </= 2 mg/dl);
- Adequate cardiac function;
- Not candidates for or have refused allogeneic transplantation;
- Patients should not be receiving azoles (ketoconazole, itraconazole, fluconazole),
macrolides, HIV protease inhibitors, cyclosporin or anti-seizure drugs
(phenobarbital, phenytoin, carbamazepine), rifampin or isoniazid.